Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01274338
Recruitment Status : Active, not recruiting
First Posted : January 11, 2011
Last Update Posted : March 19, 2018
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : May 1, 2018
  Study Completion Date : No date given